LEGN Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

KUPNO 20173 min ago

@ $52.08

Wydano: 15 bal. 2024 @ 21:17

Zwrot: -12.98%

Poprzedni sygnał: bal. 15 - 20:41

Poprzedni sygnał: Sprzedaż

Zwrot: -1.02 %

Live Chart Being Loaded With Signals

Commentary (29 bal. 2024 @ 21:31):

Stats
Dzisiejszy wolumen	657 089
Średni wolumen	974 846
Kapitalizacja rynkowa	8.24B
EPS	$0 ( 2024-03-11 )
Następna data zysków	( $-0.240 ) 2024-05-13
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-15.41
ATR14	$0.0290 (0.06%)

Wolumen Korelacja

Długi: -0.27 (neutral)

Krótki: 0.31 (neutral)

Signal:(23.245) Neutral

Legend Biotech Corp Korelacja

10 Najbardziej pozytywne korelacje
AQST	0.804

10 Najbardziej negatywne korelacje
MACQU	-0.813
CFACU	-0.811

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Legend Biotech Corp Korelacja - Waluta/Towar

-0.26
( neutral )

-0.62
( weak negative )

0.00
( neutral )

-0.23
( neutral )

0.75
( moderate )

-0.29
( neutral )

Legend Biotech Corp Finanse

Annual	2023
Przychody:	$285.14M
Zysk brutto:	$120.48M (42.25 %)
EPS:	$-2.94

FY	2023
Przychody:	$285.14M
Zysk brutto:	$120.48M (42.25 %)
EPS:	$-2.94

FY	2022
Przychody:	$117.01M
Zysk brutto:	$51.64M (44.14 %)
EPS:	$-2.81

FY	2021
Przychody:	$89.79M
Zysk brutto:	$0.00 (0.00 %)
EPS:	$-2.74

Financial Reports:

No articles found.

Legend Biotech Corp

Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery and development of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM), as well as a comparison of the treatment with standard triplet therapy in revlimid-refractory multiple myeloma. The company also has a portfolio of earlier-stage autologous product candidates, which are in Phase I clinical trials for the treatment of gastric cancer and T cell lymphoma. In addition, it is developing CAR-T product candidates targeting CD20/CD22/CD19 for the treatment of non-hodgkins lymphoma, diffuse large B-cell lymphoma, and acute lymphoblastic leukemia. Further, the company has product candidates in early preclinical and clinical development for the treatment of solid tumors as well as infectious diseases. It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel. Legend Biotech Corporation was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation is a subsidiary of Genscript Biotech Corporation.